Epitomee Medical Ltd

Tel Aviv Stock Exchange EPIT.TA

Epitomee Medical Ltd EBITDA for the year ending December 31, 2023: USD -1.37 M

Epitomee Medical Ltd EBITDA is USD -1.37 M for the year ending December 31, 2023, a 67.84% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.
  • Epitomee Medical Ltd EBITDA for the year ending December 31, 2022 was USD -4.27 M, a -54.75% change year over year.
  • Epitomee Medical Ltd EBITDA for the year ending December 31, 2021 was USD -2.76 M, a -209.08% change year over year.
  • Epitomee Medical Ltd EBITDA for the year ending December 31, 2020 was USD -892.63 K, a 3.88% change year over year.
  • Epitomee Medical Ltd EBITDA for the year ending December 31, 2019 was USD -928.69 K.
Key data
Date EBITDA Net Income EPS (Diluted) Shares (Diluted, Weighted)
Market news
Tel Aviv Stock Exchange: EPIT.TA

Epitomee Medical Ltd

CEO Dr. Radan Hashimshony Ph.D.
IPO Date Dec. 15, 2021
Location Israel
Headquarters 19 Tarshish
Employees 42
Sector Health Care
Industries
Pharmaceuticals Biotechnology
Description

Epitomee Medical Ltd, a biomedical company, develops and commercializes ingestible therapeutic devices worldwide. Its capsule is used for weight management, waist circumference reduction, and cardiovascular risk factors reduction. Epitomee Medical Ltd has a strategic partnership with Nestlé Health Science S.A. for the development and commercialization of the weight loss capsule. The company was incorporated in 2005 and is based in Caesarea, Israel.

StockViz Staff

January 15, 2025

Any question? Send us an email